BridgeBio Pharma (BBIO) Financial Analysis & Valuation | Quarter Chart
BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs inc... more
BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for ... more
Company facts
Reported company information and share structure.
Company
Share structure
| Market Cap | $13.40B | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | US | CEO | Neil Kumar |
| IPO Date | 2019-06-27 | CAGR | — |
| Employees | 999 | Website | www.bridgebio.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
BBIO chart loading...
Key metrics
Reported fundamentals and market-derived technical indicators.
Fundamentals
Technicals
| EV | $13.41B | P/E | -18.33 | Forward P/E | -305.23 | PEG | — |
| P/S | 0.02 | P/B | -0.02 | P/CF | -0.02 | P/FCF | -0.02 |
| Sales | $691.84M | Sales 1Y | 193.38% | Sales 3Y | 12090.93% | Sales 5Y | 1002.79% |
| EPS | $-3.74 | EPS 1Y | -12.47% | EPS 3Y | -9.14% | EPS 5Y | -6.53% |
| Sales QoQ | 14.36% | EPS QoQ | -7.14% | Sales QoQ Avg | 19.36% | EPS QoQ Avg | -4.48% |
| Gross Margin | 93.14% | Operating Margin | -78.56% | Profit Margin | -100.64% | ROCE | -166.38% |
| ROA | -57% | ROE | 32% | Altman Z Score | -3.5 | Piotroski Score | 3 |
| Current Ratio | 1.23 | Quick Ratio | 1.17 | Cash Ratio | 0.76 | Op. CF Ratio | -0.25 |
| Debt/Equity | -0.99 | Debt/Assets | 2.05 | Lt Debt/Equity | -0.77 | Lt Debt/Cap. | -3.28 |
| Intrst Cov. | -6.05 | Inventory Turnover | 0.9 | Asset Turnover | 0.57 | Receivables Turnover | 2.72 |
| Enterprise Value | $13.41B | P/E Ratio | -18.33 |
| Forward P/E | -305.23 | PEG Ratio | — |
| P/S Ratio | 0.02 | P/B Ratio | -0.02 |
| P/CF Ratio | -0.02 | P/FCF Ratio | -0.02 |
| EPS | $-3.74 | EPS Growth 1Y | -12.47% |
| EPS Growth 3Y | -9.14% | EPS Growth 5Y | -6.53% |
| Revenue Growth 1Y | 193.38% | Gross Margin | 93.14% |
| Operating Margin | -78.56% | Profit Margin | -100.64% |
| ROE | 32% | ROA | -57% |
| ROCE | -166.38% | Current Ratio | 1.23 |
| Quick Ratio | 1.17 | Cash Ratio | 0.76 |
| Debt/Equity | -0.99 | Interest Coverage | -6.05 |
| Altman Z Score | -3.5 | Piotroski Score | 3 |
BridgeBio Pharma (BBIO) valuation & financials
BridgeBio Pharma (BBIO) has a market capitalization of $13.40B and trades at a price-to-earnings ratio of -18.3. It operates in the Healthcare sector (Biotechnology).
BridgeBio Pharma's revenue grew +193.4% over the last year.
BridgeBio Pharma's next earnings report is scheduled for October 28, 2026 after market close (provider scheduled date); analysts estimate EPS of $-0.61. Check the earnings calendar to see all companies reporting this week.
Compare with other Healthcare companies: Eli Lilly (LLY) · Johnson & Johnson (JNJ) · AbbVie (ABBV) · UnitedHealth (UNH) · Merck (MRK) · Roche (ROG.SW)